Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study

Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study

First-line treatment with regorafenib in frail metastatic colorectal cancer (mCRC) patients has shown some benefit. To accurately identify such patients before treatment, we studied blood biomarkers and primary tumor molecules. We unveiled serum microRNAs (miRNAs), single-nucleotide polymorphisms (S...

Full description

Bibliographic Details
Main Authors: Elisa Conde, Julie Earl, Lorena Crespo-Toro, Carolina Blanco-Agudo, Edurne Ramos-Muñoz, E. Macarena Rodríguez-Serrano, Jose Carlos Martínez Ávila, Laura Salinas-Muñoz, Silvia Serrano-Huertas, Reyes Ferreiro, Mercedes Rodriguez-Garrote, Bruno Sainz, Bartomeu Massuti, Pilar García Alfonso, Manuel Benavides, Enrique Aranda, María Laura García-Bermejo, Alfredo Carrato
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Cancers
Subjects:
miRNAs
colorectal cancer
regorafenib
biomarkers
treatment response
toxicity
Online Access:https://www.mdpi.com/2072-6694/13/7/1710

Internet

https://www.mdpi.com/2072-6694/13/7/1710

Similar Items